BENGALURU (Reuters), – India’s Cipla signed a deal in which it will sell and distribute the two most-sold diabetes medications in America, according to a statement by the companies on Monday.

The companies announced that Lilly would transfer India’s rights to Trulicity products and Humalog products. However, it will maintain the existing model of operation for its remaining products.

Cipla will be able to increase access to drugs in India, which has the second highest number of diabetes patients in the world. According to estimates by government, India is home to more than 70 millions people with diabetes.

Lilly’s top-selling drug, Trulicity (a once-weekly injection to manage blood sugar throughout the week), was $1.54 Billion in second quarter sales. The company’s diabetes portfolio also includes Humalog (a quick-acting insulin injection).

“Developing strategic alliances to adopt different operating model is the key to… making innovative medicines accessible to more people… in India,” said Luca Visini Lilly’s managing Director for India.

“Cipla is a well-established organization that has strong roots in India and can expand (Trulicity & Humalog) access all over India.